Johnson & Johnson (JNJ)
NYSE · Price as of · Nasdaq Real Time Price
- Analysts22
- Implied upside+0.8%
- Target range$190.00 to $305.00
- EPS expected$2.42 -13%
- A year ago$2.80
- Revenue expected$25.19B +5.0%
- Estimate range$2.31 to $2.49
How Congress has done in JNJ
Every purchase of JNJ disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.
| Measure | JNJ | SPY |
|---|---|---|
| Median 12-month return after purchase | +7.6% | +17.6% |
| Median difference vs SPY | -4.7% | — |
| Purchases that beat SPY | 25 of 55 (45%) | — |
| Members who bought | 16 | — |
Most frequent buyers: Lloyd Doggett (13), Kevin Hern (12), Josh Gottheimer (6), Marjorie Taylor Greene (4), Jared Moskowitz (3).
These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 7 of the 55 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.
Congress trades
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-07-30 | Rich McCormick | Sale | $1,001 - $15,000 | |
| 2026-06-29 | Thomas Kean NJ | Sale | $1,001 - $15,000 | |
| 2026-06-09 | Lloyd Doggett TX | Purchase | $1,001 - $15,000 | |
| 2026-06-02 | Thomas Kean NJ | Sale | $1,001 - $15,000 | |
| 2024-10-29 | Tommy Tuberville AL | Sale | $15,001 - $50,000 |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | August 18, 2026 | FORM 4 |
| 144 | August 17, 2026 | View on EDGAR |
| 4 | August 14, 2026 | FORM 4 |
| 144 | August 13, 2026 | View on EDGAR |
| N-PX | August 11, 2026 | View on EDGAR |
| 4 | August 7, 2026 | FORM 4 |
| 4 | August 7, 2026 | FORM 4 |
| 144 | August 6, 2026 | View on EDGAR |
Frequently asked questions
When does JNJ report earnings?
Johnson & Johnson (JNJ) is scheduled to report quarterly results on October 13, 2026, before the open. The 4-analyst consensus is $2.42 per share on revenue of $25.19B for the quarter ending September 30, 2026, against $2.80 and $23.99B a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters.
What do analysts expect for JNJ?
22 analysts cover Johnson & Johnson (JNJ). The consensus rating is Buy. The average price target is $272.50, in a range of $190.00 to $305.00.
Are insiders buying or selling JNJ?
We have no qualifying Form 4 insider purchases or sales on record for Johnson & Johnson (JNJ). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Has Congress made money trading JNJ?
16 members of Congress have disclosed buying JNJ in the last 5 years, 55 purchases in total. Measured over the 12 months after each trade date, the median purchase returned +7.6% against +17.6% for SPY over the same windows, and 25 of the 55 (45%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.
Where can I see JNJ SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed August 18, 2026.